Amantadine (pharmacology) < Amantadine (therapeutic use) < Ambulatory

Facettes :

List of bibliographic references indexed by Amantadine (therapeutic use)

Number of relevant bibliographic references: 19.

Ident.	Authors (with country if any)	Title
000628 (2014)	Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. Facheris	Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
000767 (2013)	Erwan Bezard [France] ; Elisabetta Tronci ; Elsa Y. Pioli ; Qin Li ; Gregory Porras ; Anders Björklund ; Manolo Carta	Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
001562 (2011)	Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche]	Milestones in Parkinson's disease therapeutics
001C02 (2010)	Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche]	Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
002A09 (2008)	Kenichi Kashihara [Japon] ; Takaki Imamura [Japon]	Amantadine may reverse punding in Parkinson's disease—Observation in a patient
002B44 (2007)	Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]	Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
003277 (2006)	Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]	Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
003466 (2006)	Alexandre Gironell [Espagne] ; Jaime Kulisevsky [Espagne] ; Berta Pascual-Sedano [Espagne] ; David Flamarich [Espagne]	Effect of amantadine in essential tremor: A randomized, placebo‐controlled trial
003584 (2006)	Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]	Association between amantadine and the onset of dementia in Parkinson's disease
003694 (2005)	Anthony E. Lang [Canada]	Treatment of progressive supranuclear palsy and corticobasal degeneration
003811 (2005)	Cheryl Waters [États-Unis]	Other pharmacological treatments for motor complications and dyskinesias
003924 (2005)	Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]	Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
003B74 (2004)	Marcin Ach [Pologne] ; Andrzej Friedman [Pologne] ; Jarosław Sławek [Pologne] ; Mirosława Derejko [Pologne]	Quality of life in Polish patients with long‐lasting Parkinson's disease
003E21 (2004)	Yoshiaki Furukawa [Canada] ; James J. Filiano [États-Unis] ; Stephen J. Kish [Canada]	Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
004577 (2002)		Amantadine and other antiglutamate agents
004736 (2001)	Nikolaos Scarmeas [États-Unis] ; David Eidelberg [États-Unis] ; Steven J. Frucht [États-Unis]	Oculogyric‐like crises in a 92‐year‐old woman with vascular Parkinsonism
004771 (2001)	Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]	Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
004B29 (2000)	E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bösch [Autriche] ; Werner Poewe [Autriche]	Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease
004C18 (1999)	Stewart A. Factor [États-Unis] ; Eric S. Molho [États-Unis]	Transient benefit of amantadine in Parkinson's disease: The facts about the myth

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Amantadine (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Amantadine (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Amantadine (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024